124 related articles for article (PubMed ID: 3261181)
1. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype.
Lippman SM; Miller TP; Spier CM; Slymen DJ; Grogan TM
Blood; 1988 Aug; 72(2):436-41. PubMed ID: 3261181
[TBL] [Abstract][Full Text] [Related]
2. Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma.
Offit K; Ladanyi M; Gangi MD; Ebrahim SA; Filippa D; Chaganti RS
Leukemia; 1990 Sep; 4(9):625-30. PubMed ID: 2168505
[TBL] [Abstract][Full Text] [Related]
3. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma.
Slymen DJ; Miller TP; Lippman SM; Spier CM; Kerrigan DP; Rybski JA; Rangel CS; Richter LC; Grogan TM
J Clin Oncol; 1990 Jun; 8(6):986-93. PubMed ID: 2140855
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of immunophenotype in diffuse non-Hodgkin's lymphoma: with special emphasis on the clinical characteristics of T-cell lymphoma].
Chubachi A; Miura AB; Takatsu H; Yamaguchi A; Nishimura S; Nakayama Y; Akihama T; Miura S; Saitoh M; Watanuki T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1303-9. PubMed ID: 2069401
[TBL] [Abstract][Full Text] [Related]
5. [Non-Hodgkin's lymphoma: correlation of cell surface marker phenotype with clinical features and prognosis].
Okabe K; Toki H; Kimura Y; Fujii M; Kiura K; Moriwaki S
Gan To Kagaku Ryoho; 1986 Oct; 13(10):2960-4. PubMed ID: 3490224
[TBL] [Abstract][Full Text] [Related]
6. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease.
Filippa DA; Ladanyi M; Wollner N; Straus DJ; O'Brien JP; Portlock C; Gangi M; Sun M
Blood; 1996 Apr; 87(7):2905-17. PubMed ID: 8639911
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
Gisselbrecht C; Gaulard P; Lepage E; Coiffier B; Brière J; Haioun C; Cazals-Hatem D; Bosly A; Xerri L; Tilly H; Berger F; Bouhabdallah R; Diebold J
Blood; 1998 Jul; 92(1):76-82. PubMed ID: 9639502
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
Armitage JO; Vose JM; Linder J; Weisenburger D; Harrington D; Casey J; Bierman P; Sorensen S; Hutchins M; Moravec DF
J Clin Oncol; 1989 Dec; 7(12):1783-90. PubMed ID: 2585020
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
Tsartsidze E; Betaneli M
Georgian Med News; 2006 May; (134):107-9. PubMed ID: 16783081
[TBL] [Abstract][Full Text] [Related]
10. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas.
Vose JM; Peterson C; Bierman PJ; Weisenburger DD; Linder J; Harrington D; Vaughan WP; Kessinger A; Armitage JO
Blood; 1990 Jul; 76(2):424-31. PubMed ID: 1973361
[TBL] [Abstract][Full Text] [Related]
11. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
13. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
Chubachi A; Miura AB; Yamaguchi A; Nishimura S
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
[TBL] [Abstract][Full Text] [Related]
14. Immunologic markers in non-Hodgkin's lymphoma.
Freedman AS; Nadler LM
Hematol Oncol Clin North Am; 1991 Oct; 5(5):871-89. PubMed ID: 1938759
[TBL] [Abstract][Full Text] [Related]
15. Waldeyer's ring lymphomas: a clinical study from the Comprehensive Cancer Center West population based NHL registry.
Krol AD; Le Cessie S; Snijder S; Kluin-Nelemans JC; Kluin PM; Noorduk EM
Leuk Lymphoma; 2001; 42(5):1005-13. PubMed ID: 11697617
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
17. Localized primary non-Hodgkin lymphoma of the breast.
Ha CS; Dubey P; Goyal LK; Hess M; Cabanillas F; Cox JD
Am J Clin Oncol; 1998 Aug; 21(4):376-80. PubMed ID: 9708637
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
[TBL] [Abstract][Full Text] [Related]
19. Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center.
Mora J; Filippa DA; Thaler HT; Polyak T; Cranor ML; Wollner N
Cancer; 2000 Jan; 88(1):186-97. PubMed ID: 10618623
[TBL] [Abstract][Full Text] [Related]
20. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
